-
Junshi Biosciences Announces Latest Data on Urothelial Carcinoma of PD-1 Inhibitor
Time of Update: 2022-03-05
At this ASCO-GU conference, the POLARIS-03 study once again updated the 2-year survival data and biomarker analysis results of toripalimab in patients with advanced urothelial carcinoma who had failed previous systemic therapy.
-
China plans to launch a "mixed fight" plan for the booster shot of the new crown vaccine. Zhifei and CanSino were selected
Time of Update: 2022-03-05
It is clear in the training that at this stage, the procedure can be implemented in people aged 18 and above who have been vaccinated with the inactivated vaccine against the new coronavirus from Sinopharm Zhongsheng Beijing, Kexing Zhongwei, and Zhongsheng Wuhan for 6 months, and who have not completed the homologous booster immunization.
-
The seventh batch of national procurement enterprises began to declare a total of 208 product regulations
Time of Update: 2022-03-05
On February 17, Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Notice on Carrying out the Information Reporting of the Seventh Batch of State-Organized Centralized Drug Procurement".
On February 17, Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Notice on Carrying out the Information Reporting of the Seventh Batch of State-Organized Centralized Drug Procurement".
-
19 drugs have been limited in pharmacies, and provinces may drop more than 100 varieties this year
Time of Update: 2022-03-05
In addition, Shandong, Zhejiang, Shanghai, Guangdong, and Henan have successively included pharmacies into the scope of centralized procurement in the province, which also means that more drugs will be reduced in price in pharmacies in the future.
-
Zhaoke Ophthalmology Atropine Sulfate Eye Drops Starts Phase 3 Clinical Trial in China and Plans to Enroll 526 People
Time of Update: 2022-03-05
has launched a Phase 3 clinical trial of atropine sulfate eye drops (NVK-002) for delaying the progression of myopia in children, which is planned to be conducted in China.
-
Hong Kong's sudden outbreak of Lianhua Qingwen was madly robbed and prices soared by 200%
Time of Update: 2022-03-05
28 yuan Lianhua Qingwen, the hype price can reach 100 yuan On February 15, the Centre for Health Protection of the Department of Health of the Hong Kong Special Administrative Region Government announced that as of 0:00 that day, there were 1,619 new confirmed cases of new coronary pneumonia in Hong Kong (all local cases) .
-
The biomacromolecule drug industry is in the ascendant, and equipment will receive more attention
Time of Update: 2022-03-05
At present, although the domestic CDMO industry is still dominated by small-molecule CDMO companies, the field of macromolecular drugs in China has risen rapidly since around 2016, and the development momentum has become stronger in the past two years.
-
The seventh batch of national procurement applications involving 200+ enterprises has been launched!
Time of Update: 2022-03-05
By LinanThe seventh batch of national procurement applications has been launched, involving a total of 208 medicines including afatinib oral regular-release dosage form and oseltamivir oral regular-re
-
The first!
Time of Update: 2022-03-05
S. Food and Drug Administration (FDA) has approved its new drug Pyrukynd (mitapivat) for the treatment of adult patients with pyruvate kinase deficiency and hemolytic anemia .
-
The Drug Administration issued a document to strictly investigate the "certification" of licensed pharmacists
Time of Update: 2022-03-05
On January 14, the Tianjin Municipal Food and Drug Administration issued the "Notice on Further Strengthening the Use and Supervision of Licensed Pharmacists in Drug Retail Enterprises", which clearly stated that the "certification" behavior of licensed pharmacists should be strictly investigated, and 3 strict inspection measures were listed:1.
-
The value of goods exceeds 100 billion, and a glimpse of the export situation of domestic new crown vaccine in 2021
Time of Update: 2022-03-05
On August 5, General Secretary Xi Jinping stated at the first meeting of the International Forum on New Crown Vaccine Cooperation that China will strive to provide 2 billion doses of vaccines to the world in 2021 .
-
Sinopharm Rongsheng Esomeprazole Sodium for Injection obtained drug registration certificate
Time of Update: 2022-03-05
On February 17, Modern Pharmaceutical announced that its wholly-owned subsidiary Sinopharm Rongsheng received the drug registration certificate for "esomeprazole sodium for injection" approved and iss
-
Hengrui's new drug R&D pipeline revealed!
Time of Update: 2022-03-05
Table 2 Hengrui Medicine is in clinical practice in the field of lung cancerand the main product layout at the launch stageBreast Cancer LayoutBreast Cancer LayoutHER2-positive breast cancer, HR+, HER- breast cancer, BRAC mutation, TNBC and other common and rare subtypes have also achieved extensive coverage.
-
Sanofi/Regeneron's Dupixent Phase 3 clinical trial for chronic spontaneous urticaria to be discontinued
Time of Update: 2022-03-05
TextrainbowToday, Regeneron and Sanofi announced that the Phase 3 trial (CUPID STUDY B) evaluating Dupixent (dupilumab) in patients with chronic spontaneous urticaria (CSU) will be based on a prespecified interim analysis.
Reference source: Regeneron, Sanofi To Stop Dupixent Phase 3 Trial In Chronic Spontaneous Urticaria Due To Futility
-
Northeast Pharmaceutical Carboprost Tromethamine Injection was awarded the "Drug Registration Certificate"
Time of Update: 2022-03-05
On the evening of February 17, Northeast Pharmaceuticals announced that its wholly-owned subsidiary, No. 1 Pharmaceutical Carprost Tromethamine Injection, received the "Drug Registration Certificate"
-
Yiming Biotech's anti-LILRB4 antibody IO-202 received FDA Fast Track designation
Time of Update: 2022-03-05
According to public information, IO-202 is a potential "first-in-class" myeloid immune checkpoint inhibitor targeting LILRB4, which has previously been granted orphan drug designation by the FDA for the treatment of AML .
-
Technical Guidelines for Clinical Trials of New Antiviral Drugs for Novel Coronavirus Pneumonia (Trial) Released
Time of Update: 2022-03-05
Provide general technical guidance and reference for clinical trial design, implementation and evaluation of antiviral drugs for novel coronavirus pneumonia .
-
This drug market has huge potential, and the 180 billion blue ocean is about to set sail
Time of Update: 2022-03-05
With the active R&D and efforts of domestic and foreign pharmaceutical companies, a number of lung cancer drugs have been launched in China, bringing more choices for the treatment of lung cancer patients .
-
ADC: The "Magic Bullet" Road to Innovation
Time of Update: 2022-03-05
ADC drug mechanism of action, source: Antibody–drug conjugates as novel anti-cancer chemotherapeutics22Five core technologiesFive core technologiesTherefore, in terms of mechanism of action, target selection, antibody modification, Linker design, selection of toxic small molecules, and coupling methods have become the five core factors affecting ADC drug design .
-
Is AI driving the wave of small molecule drug development?
Time of Update: 2022-03-05
(Source: Nature Reviews Drug Discovery)In contrast, the combined internal development pipelines of the top 20 pharmaceutical companies contain approximately 330 disclosed discovery and preclinical projects, and approximately 430 projects in Phase I clinical development (using the same public data sources, excluding collaborative projects) ; Figure 1b) .
